Abbott debuts FreeStyle Libre 2 glucose monitoring system
People living with diabetes now have the option to use Abbott’s next-generation FreeStyle Libre 2, an integrated continuous glucose monitor.
Abbott received the Food and Drug Administration’s clearance last month for the product, which is indicated for adults and children four years of age and up.
The FreeStyle Libre 2 technology helps people manage their condition and also facilitates sharing health data with their doctors which is critical to achieving better outcomes and more efficient, safe telehealth visits.
Using Bluetooth technology, the FreeStyle Libre 2 system automatically alerts users when their glucose is high or low without needing to scan the sensor. Users also have the option of turning off the customizable, real-time alarms. The system has a combined mean absolute relative difference, a measurement of performance for CGMs, of 9.3% (9.2% for adults and 9.7% for pediatrics), making it the only iCGM sensor sustaining a high level of accuracy over 14 days, the company said.
The company outlined the key benefits of FreeStyle Libre 2, which include:
- Optional Real-Time Alarms: Only iCGM available with customizable, optional real-time alarms to alert users when their glucose is too high or low without scanning.
- Cost-Effective: Priced the same as the FreeStyle Libre 14-day system, which is about 70% less than the cost of other CGMs currently available.
- Longest-Lasting Wearable iCGM: First and only iCGM that lasts up to 14 days, providing trends, insights and actionable data that will help people make more informed decisions to reach better health outcomes.
- Unsurpassed 14-Day Accuracy and Performance: Excellent accuracy and reliable alarm performance, including when glucose levels are very low for both adults and children, giving parents peace of mind.